Could Indivior PLC Be A Better Buy Than AstraZeneca plc And Shire PLC?

Will Indivior PLC (LON:INDV) continue to outperform AstraZeneca plc (LON:AZN) and Shire PLC (LON:SHP)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Reckitt Benckiser’s pharmaceutical spin-off Indivior (LSE: INDV) has been a stunning performer this year, climbing by 76% in seven months since the firm’s shares started trading.

At first glance, this seems strange. The firm only has one product, Suboxone, which is a treatment for opioid addiction, including heroin addiction.

Since 2014, the firm has faced an onslaught of generic competition in its main market, the US. No fewer than four companies have gained approval for cheap generic alternatives to Suboxone.

Indivior’s earnings per share are expected to fall by 54% in 2015 and by 21% in 2016.

Given this, why have investors pushed the shares up so that they are trading on a 2016 P/E of 18.4, while offering a below-average 2.5% yield?

In the remainder of this article, I’ll provide two possible explanations for Indivior’s strong valuation.

I’ll also ask whether investors looking for growth and income might do better with AstraZeneca (LSE: AZN) (NYSE: AZN.US) or Shire (LSE: SHP) (NASDAQ: SHPG.US).

Option 1: Beating expectations

Indivior shares are currently priced on a historic P/E of just 8 times 2014 earnings. It’s quite possible that the firm’s earnings per share will not fall as fast as expected in 2015, which could leave the shares looking cheap.

There are three ways this might happen. Firstly, Suboxone pricing may not fall as fast as expected.

Secondly, prescription volumes are rising, as a result of US Medicaid legislation.

Finally, Suboxone has a technical advantage over its generic competitors. Indivior’s product is available as a film that dissolves on the patient’s tongue. Alternatives are only available as tablets, which can be secreted and traded for drugs by addicts.

Option 2: Pipeline delivers

Indivior does have a small number (four) of new products in development. The most advanced of these is due for patient trials this year.

It’s possible that one of these products will become a blockbuster success, replacing the patent-protected profits formerly generated by Suboxone.

However, relying on such a small pipeline to deliver a major success is risky, in my view.

What about AstraZeneca and Shire?

Patent expiries have caused AstraZeneca’s earnings per share to plunge from $7.24 in 2011 to just $0.98 in 2014.

Despite this, the firm’s shares have outperformed the FTSE 100 over the last five years. They also offer a higher yield, at 4.1%, than the FTSE 100 average of 3.6%.

AstraZeneca’s size and financial firepower has enabled the firm to convince investors that a turnaround is on the horizon. A generous takeover proposal from Pfizer also helped boost sentiment.

AstraZeneca currently trades on a forecast P/E of 16.1. In my view it remains a good long-term income growth buy.

In contrast, Shire’s growth over the last five years has been remarkable. Today, the firm’s shares are 272% higher than they were five years ago.

Like AstraZeneca, Shire’s share price has been boosted by a failed takeover bid, but earnings have risen too. Shire’s earnings per share are expected to be 140% higher in 2015 than in 2011.

However, Shire looks quite fully valued at the moment, with a 2015 forecast P/E of 22 and a yield of just 0.4%. I suspect the best of the firm’s growth has now passed, so now could be a good time to lock in some profits.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »